Group 1 - The company is currently in the market development stage for its toothpaste business, specifically the Xigua Frost toothpaste under its subsidiary, Daily Chemical Health Products [2] - The expected sales for the toothpaste in 2024 are nearly 40 million yuan, which represents a small proportion of the company's overall revenue, indicating limited contribution to performance improvement [2] - The company plans to continue optimizing its product structure, accelerate the layout of distribution channels, actively expand e-commerce channels, and enhance the terminal brand image to achieve stable and continuous sales growth [2]

格隆汇9月23日丨桂林三金(002275.SZ)在投资者互动平台表示，西瓜霜牙膏为旗下子公司日化健康产 品，目前尚处于市场开拓阶段，根据2024年度销售情况，牙膏销售额近四千万元，占公司总体营收比例 较小，对业绩提升贡献有限，未来公司将继续优化产品结构，加快流通渠道布局，积极拓展电商渠道， 完善终端品牌形象，争取实现销量持续稳定增长。 ...

格隆汇9月23日丨桂林三金(002275.SZ)在投资者互动平台表示，西瓜霜牙膏为旗下子公司日化健康产 品，目前尚处于市场开拓阶段，根据2024年度销售情况，牙膏销售额近四千万元，占公司总体营收比例 较小，对业绩提升贡献有限，未来公司将继续优化产品结构，加快流通渠道布局，积极拓展电商渠道， 完善终端品牌形象，争取实现销量持续稳定增长。 ...

Group 1: Report Core Information - Reported company: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [2] - Research date: May 20, 2025 [16] Group 2: Research Basic Information - Research object: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [16] - Reception time: 2025 - 05 - 20 [16] - Reception staff: Host, Chairman and President Zou Xun, Director, Vice - President and Financial Officer Xie Yuan'gang, Vice - President and Board Secretary Li Chun, Independent Director Chen Liang [16] Group 3: Detailed Research Institutions - Reception object: All investors [19] - Reception object type: Others [19] - Reception method: Network remote [19] Group 4: Main Content Big Pharmacy - Reason for loss: Store expansion leading to large expenditures [23] - Function: An important part of the company's marketing strategy, expanding sales channels and perfecting the industrial chain [23] Sales Revenue Composition - Main income sources: Most from Chinese patent medicines, some from chemical drugs of Hunan Sanjin, and some from daily - chemical health products [23] - Key varieties: First - tier varieties like Sanjin Tablets series and Watermelon Frost series; second - tier varieties like Xuanyunning and Gejie Dingchuan Capsules; third - tier varieties in market development stage with small proportion [23] Dividend Policy - 2024 annual equity distribution plan: Proposed to distribute 3.5 yuan per 10 shares, totaling 206 million yuan in cash dividends, and also disclosed the 2025 mid - term cash dividend plan [24] Watermelon Frost Toothpaste - Product series: Yayanqing, Classic Anti - inflammation, Qingyan Toothpaste, etc. [25] - Current situation: Currently building sales channels, listed and promoted in second - tier and lower cities nationwide, mainly through supermarket channels and supplemented by online sales. The overall scale is small but in the growth stage [25] - Future plan: Leverage the company's advantages to expand the market scale [25] Subsidiaries in Shanghai - Baifan Bio: Affected by the investment and financing environment, with some idle production capacity in the short - term, but business development and customer resource accumulation have increased compared to 2023 [25] - Baichuan Bio: Multiple project pipelines are in the new drug R & D stage, with only a small amount of income from technical services, small revenue scale, large R & D expenditure [25] - Measures: Control costs and expenses, optimize the personnel structure, hire professional consulting companies, optimize R & D pipelines, and focus on projects like BC006 monoclonal antibody injection [26] New Drug R & D Progress - Progress: Advancing steadily according to the plan, and relevant information will be announced when significant progress is made [26] Second and Third - tier Varieties - Growth trend: Overall growth is better than first - tier varieties. Gejie Dingchuan Capsules may continue last year's growth rate; Xuanyunning series aims for double - digit growth this year; Lamotrigine Tablets aim to reach 100 million yuan in sales this year; other varieties strive for continuous breakthroughs and high growth rates [26][27]